mutation of med12 is not a frequent occurrence in prostate cancer of korean patients
Clicks: 168
ID: 134873
2017
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.4
/100
168 views
23 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #23 of 38 articles by views in softwarex
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Prostate cancer is one of the major health care problems, but the molecular pathogenesis has been relatively insufficiently elucidated. Recently, whole exome sequencing of prostate cancer identified recurrent mutations involving MED12 in Caucasian patients, which finding was not reproduced in one subsequent study by Sanger sequencing. Thus, we investigated mutation status of MED12 in exons 2 and 26 by Sanger sequencing in 102 radical prostatectomy cases from Korean patients. The analysis found the mutation in none of the cases. Therefore, MED12 mutation does not appear to represent a significant molecular alteration in this cohort of patients according to the analysis by the traditional "gold standard."
| Reference Key |
yoon2017asianmutation
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Nara Yoon;Sharon Lim;So Young Kang;Ghee Young Kwon;Hwang Gyun Jeon;Byong Chang Jeong;Seong Il Seo;Seong Soo Jeon;Hyun Moo Lee;Han Yong Choi |
| Journal | softwarex |
| Year | 2017 |
| DOI |
10.4103/1008-682X.172826
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.